Key clinical point: For patients with chronic hepatitis B, daily aspirin therapy may reduce the risk of hepatocellular carcinoma.
Major finding: Daily aspirin therapy reduced the risk of hepatocellular carcinoma by 29%.
Study details: A cohort study involving 2,123 patients with chronic hepatitis B who received daily aspirin and 8,492 matched controls.
Disclosures: The study was funded by the Ministry of Science and Technology, National Health Research Institutes, and Taichung (Taiwan) Veterans General Hospital. One author reported financial compensation from Gilead and Bristol-Myers Squibb.
Lee T-Y et al. JAMA Intern Med. 2019 Mar 18..